GEN Exclusives

More »

GEN News Highlights

More »
May 11, 2011

Sosei Pays BioAlliance $3M Up Front for Japanese Rights to Oropharyngeal Candidiasis Drug

  • Sosei is paying BioAlliance Pharma $3 million up front for Japanese commercialization rights to the latter’s oropharyngeal candidasis drug Loramyc® (miconazole Lauriad™) mucoadhesive buccal tablets. BioAlliance could receive another $15.5 million in commercialization and milestone payments, plus future royalties from sales in Japan. Loramyc is already approved in 28 countries including the EU, U.S. (where it is trade-named Oravig™), and Korea.

    Loramyc is based on BioAlliance’s Lauriad oral delivery technology, which specifically targets the mucus membranes without systemic transfer. In March BioAlliance received €743,000 (roughly $1.1 million) from Fond Unique Interministériel (a French program supporting collaborative research projects) to support research within a €2 million (about $2.9 million) collaborative program that aims to establish proof-of-concept for delivering biological products via the mucosal route. The first potential application will be a peptide delivered using the Lauriad mucoadhesive technology.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »